Newsroom | 37084 results

Sorted by: Latest

Medical Devices
-

Quanterix Releases Financial Results for the Second Quarter of 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2025. “Through our combination with Akoya Biosciences, we have created a high-margin, high-throughput business with a compelling opportunity to deliver profitable growth in an expanded market,” said Masoud Toloue, CEO of Quanterix. “We have built a franchise that is gen...
-

Owlet Reports Second Quarter 2025 Financial Results; Increases Full Year 2025 Guidance; Announces CEO Transition Plan

LEHI, Utah--(BUSINESS WIRE)--Owlet, Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today reports financial results for the second quarter ended June 30, 2025. Owlet’s Chief Executive Officer and Co-Founder, Kurt Workman; President, Jonathan Harris; and Chief Financial Officer, Amanda Twede Crawford, will host a conference call to review the Company’s results and provide a business and corporate update today, August 7, 2025, at 4:30 p.m. ET. Q2 2025 Financia...
-

Varex Announces Financial Results for Third Quarter Fiscal Year 2025

SALT LAKE CITY--(BUSINESS WIRE)--Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the third quarter of fiscal year 2025. 3QFY25 Summary Revenues of $203 million GAAP gross margin 33% | Non-GAAP gross margin* 34% GAAP operating margin (40)% | Non-GAAP operating margin* 8% GAAP net loss $(2.15) per diluted share | Non-GAAP net earnings* $0.18 per diluted share Cash flow from operations was $8 million Sunny Sanyal, Chief Executive Officer, stated, "We ar...
-

Sensus Healthcare Reports Second Quarter 2025 Financial Results

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announces financial results for the three and six months ended June 30, 2025. Highlights of the second quarter of 2025 and subsequent weeks include the following: Revenues were $7.3 million, compared with $9.2 million in the prior-year quarter Net l...
-

Inogen Announces Second Quarter 2025 Financial Results

GOLETA, Calif.--(BUSINESS WIRE)--Inogen Announces Second Quarter 2025 Financial Results; Delivered strong top-line results; raising full year 2025 revenue expectations...
-

Allurion to Report Second Quarter 2025 Financial Results on August 13, 2025

NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that it will report financial results for the second quarter 2025 on Wednesday, August 13, 2025. Company management will host a conference call to discuss financial results and provide a business update on the same day at 8:30 AM ET. To access the conference call by telephone, please dial (888) 330-3417 (domestic) or +1 (646) 960...
-

BlinkRx Launches “Operation Access Now” to Accelerate and Scale Direct‑to‑Patient and Direct‑to‑Business Programs

NEW YORK--(BUSINESS WIRE)--BlinkRx, the nation's leading prescription lifecycle management platform, today announced the launch of Operation Access Now, a rapid deployment initiative that enables pharmaceutical manufacturers to build and launch direct-to-patient (DTP) and direct‑to‑business (DTB) channels that expand medication access and deliver pricing transparency in as little as 21 days. This program comes at a moment of growing urgency across the life sciences industry. As traditional acce...
-

QinFlow Launches Advanced Fluid and Blood Warming Solution to Meet Critical Needs in ORs and ICUs

PLANO, Texas--(BUSINESS WIRE)--QinFlow has launched its newest advanced fluid and blood warming solution to meet a critical need in hospital ORs and ICUs....
-

Orpyx Launches Sensory Insole Program to Combat >$80B Annual Cost of Diabetic Foot Complications

CALGARY, Alberta--(BUSINESS WIRE)--Orpyx launches next-gen sensory insole program to prevent diabetic foot ulcers, reduce costs, and support value-based care through remote monitoring....
-

ThinkBio.Ai® and UST Partner to Strengthen AI Enablement Capabilities for Biopharma and Healthcare Organizations

ALISO VIEJO, Calif.--(BUSINESS WIRE)--ThinkBio.Ai® and UST Partner to Strengthen AI Enablement Capabilities for Biopharma and Healthcare Organizations....